Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,931 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Case report: Long-term survival of a pancreatic cancer patient immunized with an SVN-2B peptide vaccine.
Shima H, Kutomi G, Satomi F, Imamura M, Kimura Y, Mizuguchi T, Watanabe K, Takahashi A, Murai A, Tsukahara T, Kanaseki T, Hirohashi Y, Iwayama Y, Tsuruma T, Kameshima H, Sato N, Torigoe T, Takemasa I. Shima H, et al. Among authors: takahashi a. Cancer Immunol Immunother. 2018 Oct;67(10):1603-1609. doi: 10.1007/s00262-018-2217-x. Epub 2018 Aug 1. Cancer Immunol Immunother. 2018. PMID: 30069687 Free PMC article.
Phase I clinical study of anti-apoptosis protein survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancer.
Honma I, Kitamura H, Torigoe T, Takahashi A, Tanaka T, Sato E, Hirohashi Y, Masumori N, Tsukamoto T, Sato N. Honma I, et al. Among authors: takahashi a. Cancer Immunol Immunother. 2009 Nov;58(11):1801-7. doi: 10.1007/s00262-009-0691-x. Epub 2009 Mar 18. Cancer Immunol Immunother. 2009. PMID: 19294381 Free PMC article. Clinical Trial.
Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer.
Miyazaki A, Kobayashi J, Torigoe T, Hirohashi Y, Yamamoto T, Yamaguchi A, Asanuma H, Takahashi A, Michifuri Y, Nakamori K, Nagai I, Sato N, Hiratsuka H. Miyazaki A, et al. Among authors: takahashi a. Cancer Sci. 2011 Feb;102(2):324-9. doi: 10.1111/j.1349-7006.2010.01789.x. Epub 2010 Dec 10. Cancer Sci. 2011. PMID: 21143701 Free article. Clinical Trial.
Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients.
Kameshima H, Tsuruma T, Torigoe T, Takahashi A, Hirohashi Y, Tamura Y, Tsukahara T, Ichimiya S, Kanaseki T, Iwayama Y, Sato N, Hirata K. Kameshima H, et al. Among authors: takahashi a. Cancer Sci. 2011 Jun;102(6):1181-7. doi: 10.1111/j.1349-7006.2011.01918.x. Epub 2011 Apr 24. Cancer Sci. 2011. PMID: 21371173 Free article. Clinical Trial.
Immunotherapeutic benefit of α-interferon (IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients.
Kameshima H, Tsuruma T, Kutomi G, Shima H, Iwayama Y, Kimura Y, Imamura M, Torigoe T, Takahashi A, Hirohashi Y, Tamura Y, Tsukahara T, Kanaseki T, Sato N, Hirata K. Kameshima H, et al. Among authors: takahashi a. Cancer Sci. 2013 Jan;104(1):124-9. doi: 10.1111/cas.12046. Epub 2012 Dec 16. Cancer Sci. 2013. PMID: 23078230 Free PMC article. Clinical Trial.
Peptide vaccinations elicited strong immune responses that were reboosted by anti-PD1 therapy in a patient with myxofibrosarcoma.
Tsukahara T, Watanabe K, Murata K, Takahashi A, Mizushima E, Shibayama Y, Kameshima H, Hatae R, Ohno Y, Kawahara R, Murai A, Nakatsugawa M, Kubo T, Kanaseki T, Hirohashi Y, Terui T, Asanuma H, Hasegawa T, Sato N, Torigoe T. Tsukahara T, et al. Among authors: takahashi a. Cancer Immunol Immunother. 2020 Feb;69(2):189-197. doi: 10.1007/s00262-019-02455-0. Epub 2019 Dec 18. Cancer Immunol Immunother. 2020. PMID: 31853575 Free PMC article.
Cytotoxic T lymphocytes efficiently recognize human colon cancer stem-like cells.
Inoda S, Hirohashi Y, Torigoe T, Morita R, Takahashi A, Asanuma H, Nakatsugawa M, Nishizawa S, Tamura Y, Tsuruma T, Terui T, Kondo T, Ishitani K, Hasegawa T, Hirata K, Sato N. Inoda S, et al. Among authors: takahashi a. Am J Pathol. 2011 Apr;178(4):1805-13. doi: 10.1016/j.ajpath.2011.01.004. Am J Pathol. 2011. PMID: 21435460 Free PMC article.
HSP DNAJB8 controls tumor-initiating ability in renal cancer stem-like cells.
Nishizawa S, Hirohashi Y, Torigoe T, Takahashi A, Tamura Y, Mori T, Kanaseki T, Kamiguchi K, Asanuma H, Morita R, Sokolovskaya A, Matsuzaki J, Yamada R, Fujii R, Kampinga HH, Kondo T, Hasegawa T, Hara I, Sato N. Nishizawa S, et al. Among authors: takahashi a. Cancer Res. 2012 Jun 1;72(11):2844-54. doi: 10.1158/0008-5472.CAN-11-3062. Epub 2012 May 2. Cancer Res. 2012. PMID: 22552285 Free article.
SYT-SSX breakpoint peptide vaccines in patients with synovial sarcoma: a study from the Japanese Musculoskeletal Oncology Group.
Kawaguchi S, Tsukahara T, Ida K, Kimura S, Murase M, Kano M, Emori M, Nagoya S, Kaya M, Torigoe T, Ueda E, Takahashi A, Ishii T, Tatezaki S, Toguchida J, Tsuchiya H, Osanai T, Sugita T, Sugiura H, Ieguchi M, Ihara K, Hamada K, Kakizaki H, Morii T, Yasuda T, Tanizawa T, Ogose A, Yabe H, Yamashita T, Sato N, Wada T. Kawaguchi S, et al. Among authors: takahashi a. Cancer Sci. 2012 Sep;103(9):1625-30. doi: 10.1111/j.1349-7006.2012.02370.x. Epub 2012 Aug 7. Cancer Sci. 2012. PMID: 22726592 Free PMC article. Clinical Trial.
4,931 results